Related Experiment Video
Updated: Mar 30, 2026

Intracellular Refolding Assay
Published on: January 24, 2012
A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS
Marianna Halasi1, Renáta Váraljai2, Elizaveta Benevolenskaya2
1From the Departments of Medicine and.
Abstract:
The oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers, and it is a potential target for anticancer therapy. We identified proteasome inhibitors as the first type of drugs that target FOXM1 in cancer cells. Here we found that HSP90 inhibitor PF-4942847 and heat shock also suppress FOXM1. The common effector, which was induced after treatment with proteasome and HSP90 inhibitors or heat shock, was the molecular chaperone HSP70. We show that HSP70 binds to FOXM1 following proteotoxic stress and that HSP70 inhibits FOXM1 DNA-binding ability. Inhibition of FOXM1 transcriptional autoregulation by HSP70 leads to the suppression of FOXM1 protein expression. In addition, HSP70 suppression elevates FOXM1 expression, and simultaneous inhibition of FOXM1 and HSP70 increases the sensitivity of human cancer cells to anticancer drug-induced apoptosis. Overall, we determined the unique and novel mechanism of FOXM1 suppression by proteasome inhibitors.
Insights
Proteasome inhibitors suppress the oncogenic FOXM1 protein by inducing heat shock protein 70 (HSP70). This novel mechanism reveals HSP70 as a key player in targeting FOXM1 for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The transcription factor FOXM1 is frequently overexpressed in human cancers, making it a promising target for anticancer therapies.
- Proteasome inhibitors were previously identified as the first class of drugs capable of targeting FOXM1 in cancer cells.
Purpose of the Study:
- To elucidate the molecular mechanisms by which proteasome inhibitors suppress FOXM1.
- To investigate the role of heat shock proteins (HSPs) in FOXM1 regulation under proteotoxic stress.
Main Methods:
- Treatment of cancer cells with proteasome inhibitors, HSP90 inhibitor PF-4942847, and heat shock.
- Analysis of FOXM1 and HSP70 expression levels and interactions.
- Assessment of HSP70 binding to FOXM1 and its effect on FOXM1 DNA-binding ability and transcriptional activity.
- Evaluation of cancer cell sensitivity to apoptosis induction.
Main Results:
- Both proteasome inhibitors and HSP90 inhibition/heat shock lead to the induction of the molecular chaperone HSP70.
- HSP70 binds to FOXM1 following proteotoxic stress, inhibiting its DNA-binding ability and transcriptional autoregulation.
- This inhibition results in decreased FOXM1 protein expression.
- Suppression of HSP70 leads to increased FOXM1 expression, while simultaneous inhibition of FOXM1 and HSP70 enhances cancer cell sensitivity to apoptosis.
Conclusions:
- A novel mechanism for FOXM1 suppression by proteasome inhibitors involves the induction of HSP70.
- HSP70 directly inhibits FOXM1 activity and protein levels, offering a new therapeutic strategy.
- Targeting both FOXM1 and HSP70 may enhance the efficacy of anticancer drugs by increasing apoptosis.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

